Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 4/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632488 | 0.87 | AR (0.48) | ARKDM4ELMNATSHRRECQL | |
| SCHEMBL16632728 | 0.87 | AR (0.46) | SLC6A4ARSLC22A12KDM4ELMNA | |
| SCHEMBL16632394 | 0.86 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3KCNH2AR | |
| SCHEMBL16632433 | 0.84 | TTR (0.44) | SLC6A4SLC6A2SLC6A3KCNH2AR | |
| SCHEMBL16632561 | 0.83 | AR (0.41) | SLC6A4ARSLC22A12KDM4ELMNA | |
| SCHEMBL16632347 | 0.82 | GRM5 (0.41) | ARSLC22A12KDM4ELMNATSHR | |
| SCHEMBL16632585 | 0.81 | AR (0.45) | SLC6A4SLC6A2SLC6A3KCNH2AR | |
| SCHEMBL16632481 | 0.80 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2AR | |
| SCHEMBL16632647 | 0.76 | L3MBTL1 (0.47) | SLC6A4LMNA | |
| SCHEMBL16632447 | 0.75 | AR (0.39) | ARSLC22A12LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | SLC6A4 4266/4885SLC6A2 3227/4885SLC6A3 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.